Antiepileptic drugs and bone disease

Clinical Reviews in Bone and Mineral Metabolism

Volumn 2, Issue 2, 2004, Pages 159-165

  Pack, Alison M ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Antiepileptic drugs; Bone mineral density; Disorders of bone and mineral metabolism; Osteoporosis; Vitamin D

Indexed keywords

ANTICONVULSIVE AGENT; CALCITONIN; CARBAMAZEPINE; CYTOCHROME P450; LAMOTRIGINE; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN D; VITAMIN K GROUP;

ADOLESCENT; BONE DISEASE; BONE TURNOVER; CALCIUM ABSORPTION; CASE REPORT; CATABOLISM; DISEASE ASSOCIATION; EPILEPSY; EVALUATION; EVIDENCE BASED MEDICINE; FRACTURE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MALE; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; REGULATORY MECHANISM; REVIEW; RICKETS; VITAMIN K DEFICIENCY;

EID: 4143069471     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:2:2:159     Document Type: Review

References (58)

1. Kruse R. 1968 Osteopathien bei antiepileptischer Langzeittherapie. Monatasschr Kinderheilkd 116:378-381.
2. Dent CE, Richens A, Rowe DFJ, et al. 1970 Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 4:69-72.
3. Richens A, Rowe DFJ. 1970 Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 14:73-76.
4. Hunter J, Maxwell JD, Stewart DA, Parsons V. Williams R. 1971 Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J 4(781):202-204.
5. Hoikka V, Savolainen K, Esko M, et al. 1981 Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scan 64:122-131.
6. Stephen LJ, McLellan AR, Harrison JH, et al. 1999 Bone density and antiepileptic drugs: a case controlled study. Seizure 8(6):339-342.
7. Sheth RD, Wesolowski CA, Jacob JC, et al. 1995 Effect of carbamazapine and valproate on bone mineral density. J Pediatr 127:256-262.
8. Chung, S., Ahn, C. 1994 Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 16:382-385.
9. Timperlake RW, Cook SD, Thomas KA, et al. 1988 Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population. J Pediatr Orthop 8:467-470.
10. Valimaki MJ, Tiihonen M, Laitinen K, et al. 1994 Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J. Bone Miner Res 9:631-637.
11. Sato Y, Kondo I, Ishida S, et al. 2001 Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57:445-449.
12. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. 2002 Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58:1348-1353.
13. Andress DL, Ozuna J, Tirschwell D, et al. 2002 Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59:781-786.
14. Tsukahara H, Kimura K, Todoroki Y, et al. 2002 Bone mineral status in ambulatory pediatric patients on long-term anti-epilepstic drug therapy. Pediatrics Internatiuonal 44:247-253.
15. Klein G. 1999 Nutritional rickets, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Favus MJ, Christakos S, Goldring SR, et al., eds, Lippincott, Williams & Wilkins, New York, NY, pp. 315-319.
16. Hahn TJ, Hendin BA, Scharp CR, et al. 1975 Serum 25-hydroxy calciferol levels and bone mass in children on chronic anti-epileptic therapy. N Engl J Med 292:550-554.
17. Guo C, Ronen GM, Atkinson SA. 2001 Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42(9):1141-1147.
18. Mosekilde L, Melsen F. 1980 Dynamic differences in trabecular bone remodeling between patients after jejuno-ileal bypass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis Relat Res 2:77-78
19. Weinstein RS, Bryce GF, Sappington LJ, et al. 1984 Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 58:1003-1009.
20. Marcus R. 1992 Secondary forms of osteoporosis, in Disorders of Bone and Mineral Metabolism, Fredric L. Coe and Murray J. Favus, eds, Raven Press, New York, NY, pp. 889-904.
21. LeBlanc AD, Evans HJ, Marsh C, Schneider V, Johnson PC, Jhingran SG. 1986 Precision of dual photon absorptiometry measurements. J Nucl Med 27:1362-1365.
22. Verrotti A, Greco R, Morgese G, et al. 2000 Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47:385-388.
23. Verrotti A, Greco R, Latini G, et al. 2002 Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43:1488-1492.
24. Jaglal SB, Kreiger N, Darlington GA. 1995 Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol 5(4):321-324.
25. Cummings SR, Nevitt MC, Browner WS, et al. 1995 Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332(12):767-773.
26. Desai KB, Ribbans WJ, Taylor GJ. 1996 Incidence of five common fractures in an institutionalized epileptic population. Injury 27(2):97-100.
27. Espallargues M, Sampietro-Colom L, Estrada MD, et al. 2001 Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int 12:811-822.
28. Vestergaard P, Tigaran S, Rejnmark L, et al. 1999 Fracture risk is increased in epilepsy. Acta Neurol Scand 99:269-275.
29. Christiansen C, Rodbro P, Lund M. 1973 Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J 4:695-701.
30. Fischer MH, Adkins WN Jr, Liebl BH, et al. 1988 Bone status in nonambulant epileptic institutionalized youth. Clin Pediatr 10:499-505.
31. Pluskiewicz W, Nowakowska J. 1997 Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound in Med and Biol 23(4):553-558.
32. Pedrera JD, Canal ML, Carvajal J, et al. 2000 Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 30(10):895-899.
33. Hahn TJ, Hendin BA, Scharp CR. 1972 Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287(18):900-904.
34. Bouillon R, Reynaert J, Claes JH, et al. 1975 The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 41:1130.
35. Berry JL, Mawer EB, Walker DA, et al. 1983 Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients, in Antiepileptic therapy: chronic toxicity of antiepileptic drugs, Oxley J, Janz D, Meinardi H, eds, Raven Press, New York, NY, pp. 185-192.
36. Gough H, Goggin T, Bissessar A, et al. 1986 A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Quarterly J. of Med 230:569-577.
37. O'Hare JA, Duggan B, O'Driscoll D, et al. 1980 Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 62:282-286.
38. Bogliun G, Beghi E, Crespi V, et al. 1986 Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 74:284-288.
39. Skillen AW, Peirides AM. 1976 Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chim Acta 72:245-251.
40. Okesina AB, Donaldson D, Lascelles PT. 1991 Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol 44:480-482.
41. Davie MW, Emberson CE, Lawson DEM, et al. 1983 Low plasma 25-hydroxyvitamin D and serum calcium in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Qual J Med 205:79-91.
42. Stamp TCB, Round JM, Haddad JG. 1972 Plasma levels and therpeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Br Med J 4:9-12.
43. Tjellesen L, Christiansen C. 1982 Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand 66:335-341.
44. Pack AM, Morrell MJ, Randall A, Flynn KL, Done S, Flaster E. 2003 Markers of general bone function, bone formation, and bone resorption in women with epilepsy on antiepileptic drug monotherapy, Neurology 60(5):S54.004.
45. Sato Y, Kondo I, Ishida S, et al. 2001 Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57:445-449.
46. Tjellesen L, Nilas L, Christiansen C. 1983 Does carbamazepine cause disturbances in calcium metabolism in epileptic patients? Acta Neurol Scand 68:13-19.
47. Tjellesen L, Gotfredsen A, Christiansen C. Effect of vitamin D 2 and D3 on bone-mineral content in carbamazepine-treated epileptic patients. 1983 Acta Neurol Scand 68 424-428.
48. Hoikka V, Alhava EM, Karjalainen P, et al, 1984 Carbamazepine and bone mineral metabolism. Acta Neurol Scand 69:77-80.
49. Bramswig S, Zitterman A, Berthold HK. 2003 Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int 73:356-360.
50. Pack AM and Morrell MJ. 2001 Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms, and therapeutic implications. CNS drugs 15(8):633-642.
51. Perucca E. 1987 Clinical implications of hepatic microsomal enzyme induction by anti-epileptic drugs. Pharmacol Ther 33:130-144.
52. Koch HV, Kratf D, von Herrath D. 1972 Influence of diphenylhydantoin and Phenobarbital on intestinal calcium transport in the rat. Epilepsia 13:829-841.
53. Takahashi A, Ondera K, Shinoda H, et al. 2000 Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 82:82-84.
54. Feldcamp J, Becker A, Witte OW, et al. 2000 Long-term anticonvulsant therapy leads to low bone mineral density-evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108(1):37-43.
55. Braam LAJLM, Knapen MHJ, Geusens P. 2003 Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calc Tissue Int 73(1):21-6.
56. Ondera K, Takahashi A, Sakurada S, et al. 2002 Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 70(13):1533-1542.
57. Vernillo AT, Rifkin BR, Hauschka PV. 1990 Phenytoin affects osteoblastic secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11:309-312.
58. Collins N, Maher J, Cole M, et al. 1991 A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 78:113-122.